Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant nivolumab versus placebo after resection for esophageal or gastroesophageal junction cancer
NL-OMON47538Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nivolumab in esophageal cancer and esophagogastric junction cancer, sponsored by Bristol Myers Squibb. Primary endpoints: Overall survival and Disease-free survival. Started Dec 2016; status: recruiting.
02
Drugs
03
Conditions
esophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on NL-OMON47538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47538.